The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review

[1]  I. Boutron,et al.  Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19 , 2021, Journal of Clinical Epidemiology.

[2]  D. Parums.  Editorial: Review Articles, Systematic Reviews, Meta-Analysis, and the Updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Guidelines , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[3]  D. Kopans.  The wisdom trial is based on faulty reasoning and has major design and execution problems , 2020, Breast Cancer Research and Treatment.

[4]  S. Cross,et al.  Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. , 2020, American journal of human genetics.

[5]  I. Boutron,et al.  The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic , 2020, Annals of Internal Medicine.

[6]  Matthew S. Lebo,et al.  Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions , 2020, Nature Communications.

[7]  Jingmei Li,et al.  European polygenic risk score for prediction of breast cancer shows similar performance in Asian women , 2020, Nature Communications.

[8]  G. Guyatt,et al.  Drug treatments for covid-19: living systematic review and network meta-analysis , 2020, BMJ.

[9]  Marc S. Williams,et al.  Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three Major Racial and Ethnic Groups. , 2020, American journal of human genetics.

[10]  Audrey Y. Chu,et al.  Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers , 2020, Nature Medicine.

[11]  Alicia R. Martin,et al.  Clinical use of current polygenic risk scores may exacerbate health disparities , 2019, Nature Genetics.

[12]  Kristen S Purrington,et al.  Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes , 2018, American Journal of Human Genetics.

[13]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[14]  P. Visscher,et al.  10 Years of GWAS Discovery: Biology, Function, and Translation. , 2017, American journal of human genetics.

[15]  R. Green,et al.  Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). , 2016, Circulation.

[16]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[17]  J. Witte,et al.  Comparison of missing data approaches in linkage analysis , 2003, BMC Genetics.

[18]  P. Visscher,et al.  Meta-analysis of the heritability of human traits based on fifty years of twin studies. , 2015, Nature genetics.

[19]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.